{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:24:34Z","timestamp":1780327474668,"version":"3.54.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jgar.2021.02.012","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T12:48:00Z","timestamp":1614689280000},"page":"18-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Risk factors for development of initial Clostridioides difficile infection"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6006-7894","authenticated-orcid":false,"given":"Jamie L.","family":"Wagner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla R.","family":"Stover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison M.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie E.","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2021.02.012_bib0005","series-title":"Antibiotic resistance threats in the United States","author":"US Centers for Disease Control and Prevention (CDC)","year":"2019"},{"key":"10.1016\/j.jgar.2021.02.012_bib0010","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMra1403772","article-title":"Clostridium difficile infection","volume":"372","author":"Leffler","year":"2015","journal-title":"N Engl J Med"},{"issue":"Suppl. 2","key":"10.1016\/j.jgar.2021.02.012_bib0015","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1093\/cid\/civ140","article-title":"Current trends in the epidemiology and outcomes of Clostridium difficile infection","volume":"60","author":"Evans","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.02.012_bib0020","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jhin.2012.12.019","article-title":"Comparison of treatment outcomes with vancomycin alone versus combination therapy in severe Clostridium difficile infection","volume":"85","author":"Bass","year":"2013","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.jgar.2021.02.012_bib0025","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/cid\/civ409","article-title":"The addition of intravenous metronidazole to oral vancomycin is associated with improved mortality in critically ill patients with Clostridium difficile infection","volume":"61","author":"Rokas","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.02.012_bib0030","doi-asserted-by":"crossref","first-page":"6113","DOI":"10.1128\/AAC.00816-15","article-title":"Age-stratified treatment response rates in hospitalized patients with Clostridium difficile infection treated with metronidazole","volume":"59","author":"Pham","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.02.012_bib0035","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/jac\/dkv453","article-title":"Efficacy of vancomycin extended-dosing regimens for treatment of simulated Clostridium difficile infection within an in vitro human gut model","volume":"71","author":"Crowther","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.02.012_bib0040","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/651706","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)","volume":"31","author":"Cohen","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jgar.2021.02.012_bib0045","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1086\/658336","article-title":"Comparison of clinical severity score indices for Clostridium difficile infection","volume":"32","author":"Fujitani","year":"2011","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jgar.2021.02.012_bib0050","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1001\/jamainternmed.2015.4114","article-title":"Overdiagnosis of Clostridium difficile infection in the molecular test era","volume":"175","author":"Polage","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jgar.2021.02.012_bib0055","doi-asserted-by":"crossref","first-page":"630","DOI":"10.7150\/ijms.30739","article-title":"Clostridium difficile infection risk with important antibiotic classes: an analysis of the FDA Adverse Event Reporting System","volume":"16","author":"Teng","year":"2019","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.jgar.2021.02.012_bib0060","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jiph.2019.11.005","article-title":"Incidence, outcome, and risk factors for recurrence of nosocomial Clostridioides difficile infection in adults: a prospective cohort study","volume":"13","author":"Karaoui","year":"2020","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.jgar.2021.02.012_bib0065","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.3748\/wjg.v23.i35.6500","article-title":"Proton pump inhibitors therapy and risk of Clostridium difficile infection: systemic review and meta-analysis","volume":"23","author":"Trifan","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jgar.2021.02.012_bib0070","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/jamainternmed.2017.0212","article-title":"Association of gastric acid suppression with recurrent Clostridium difficile infection: a systematic review and meta-analysis","volume":"177","author":"Tariq","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jgar.2021.02.012_bib0075","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cix1085","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.02.012_bib0080","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1473-3099(17)30235-9","article-title":"Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study","volume":"17","author":"Vickers","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.jgar.2021.02.012_bib0085","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1093\/cid\/cis462","article-title":"Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin","volume":"55","author":"Cornely","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"21","key":"10.1016\/j.jgar.2021.02.012_bib0090","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1001\/jama.2009.1754","article-title":"International study of the prevalence and outcomes of infection in intensive care units","volume":"302","author":"Vincent","year":"2009","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.jgar.2021.02.012_bib0095","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1017\/S0950268815000552","article-title":"Epidemiology of Clostridium difficile infection: results of a hospital-based study in Krakow, Poland","volume":"143","author":"Czepiel","year":"2015","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.jgar.2021.02.012_bib0100","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s10096-019-03539-6","article-title":"Clostridium difficile infection: review","volume":"38","author":"Czepiel","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521000448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521000448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:56:15Z","timestamp":1761990975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716521000448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":20,"alternative-id":["S2213716521000448"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2021.02.012","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors for development of initial Clostridioides difficile infection","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2021.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}